Protagonist Therapeutics (PTGX) Reports Q4 Loss of $0.15

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Protagonist Therapeutics (PTGX) Reports Q4 Loss of $0.15

Protagonist Therapeutics (PTGX) PT Trimmed to $42 at BMO Capital, But Sees Catalyst-Rich 2018

March 8, 2018 5:47 AM EST

BMO Capital analyst M. Ian Somaiya lowered his price target on Protagonist Therapeutics (NASDAQ: PTGX) to $42.00 (from $44.00) while maintaining an Outperform rating.

Somaiya notes Protagonists low risk pipeline is quickly maturing with an interim analysis (futility) of the Phase 2b... More